Related Experiment Video

Updated: Oct 13, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

[Controversy about using calcium antagonists for treatment of coronary disease and hypertension]

J Głuszek1, K Pawlaczyk-Gabriel

  • 1Kliniki Nadciśnienia Tetniczego Instytutu Kardiologii Akademii Medycznej w Poznaniu.

Przeglad Lekarski
|January 1, 1997
PubMed

Insights

Calcium antagonists are effective for hypertension and angina but may increase mortality risk. Short-acting nifedipine should be avoided; further trials will clarify risks of other calcium antagonists.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Calcium antagonists are widely prescribed for hypertension and angina pectoris.
  • They offer good efficacy with fewer metabolic side effects compared to beta-blockers and diuretics.
  • Unlike beta-blockers and diuretics, their impact on mortality from myocardial infarctions and strokes is not well-established.

Purpose:

  • To discuss potential harmful mechanisms of calcium antagonists.
  • To evaluate risks associated with different classes and formulations of calcium antagonists.
  • To review evidence regarding calcium antagonists and mortality from myocardial infarctions and strokes.

Summary:

  • Meta-analyses from 1995 suggest certain calcium antagonists may increase mortality.
  • Short-acting nifedipine formulations are implicated and should be withdrawn from therapy for chronic hypertension and angina pectoris.
  • The paper examines pathogenetic mechanisms and drug-specific effects, including duration of action.

Impact:

  • Highlights the need for caution with specific calcium antagonist formulations.
  • Suggests potential risks associated with calcium antagonists, contrasting with established benefits of other drug classes.
  • Ongoing trials are crucial to determine the overall safety and utility of various calcium antagonists in cardiovascular therapy.

More Related Videos

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...